Report cover image

Global Phosphoinositide 3-Kinase Inhibitor Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 195 Pages
SKU # APRC20361429

Description

Summary

According to APO Research, The global Phosphoinositide 3-Kinase Inhibitor market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Phosphoinositide 3-Kinase Inhibitor include Gilead Sciences Inc., Secura Bio, Inc., TG Therapeutics Inc., Bayer AG and Novartis AG, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Phosphoinositide 3-Kinase Inhibitor, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Phosphoinositide 3-Kinase Inhibitor, also provides the revenue of main regions and countries. Of the upcoming market potential for Phosphoinositide 3-Kinase Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Phosphoinositide 3-Kinase Inhibitor revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Phosphoinositide 3-Kinase Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Phosphoinositide 3-Kinase Inhibitor revenue, projected growth trends, production technology, application and end-user industry.

Phosphoinositide 3-Kinase Inhibitor Segment by Company

Gilead Sciences Inc.
Secura Bio, Inc.
TG Therapeutics Inc.
Bayer AG
Novartis AG
Phosphoinositide 3-Kinase Inhibitor Segment by Type

Dual PI3K/mTOR inhibitors
Pan-PI3K Inhibitors
Other
Phosphoinositide 3-Kinase Inhibitor Segment by Application

FL - Follicular Iymphoma
CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma
Other Indications
Phosphoinositide 3-Kinase Inhibitor Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phosphoinositide 3-Kinase Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Phosphoinositide 3-Kinase Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phosphoinositide 3-Kinase Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Phosphoinositide 3-Kinase Inhibitor in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Phosphoinositide 3-Kinase Inhibitor company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Phosphoinositide 3-Kinase Inhibitor revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Phosphoinositide 3-Kinase Inhibitor Market by Type
1.2.1 Global Phosphoinositide 3-Kinase Inhibitor Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Dual PI3K/mTOR inhibitors
1.2.3 Pan-PI3K Inhibitors
1.2.4 Other
1.3 Phosphoinositide 3-Kinase Inhibitor Market by Application
1.3.1 Global Phosphoinositide 3-Kinase Inhibitor Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 FL - Follicular Iymphoma
1.3.3 CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma
1.3.4 Other Indications
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Phosphoinositide 3-Kinase Inhibitor Market Dynamics
2.1 Phosphoinositide 3-Kinase Inhibitor Industry Trends
2.2 Phosphoinositide 3-Kinase Inhibitor Industry Drivers
2.3 Phosphoinositide 3-Kinase Inhibitor Industry Opportunities and Challenges
2.4 Phosphoinositide 3-Kinase Inhibitor Industry Restraints
3 Global Growth Perspective
3.1 Global Phosphoinositide 3-Kinase Inhibitor Market Perspective (2020-2031)
3.2 Global Phosphoinositide 3-Kinase Inhibitor Growth Trends by Region
3.2.1 Global Phosphoinositide 3-Kinase Inhibitor Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Phosphoinositide 3-Kinase Inhibitor Market Size by Region (2020-2025)
3.2.3 Global Phosphoinositide 3-Kinase Inhibitor Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Players
4.1.1 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Players (2020-2025)
4.1.2 Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Players (2020-2025)
4.1.3 Global Phosphoinositide 3-Kinase Inhibitor Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Phosphoinositide 3-Kinase Inhibitor Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Phosphoinositide 3-Kinase Inhibitor Key Players Headquarters & Area Served
4.4 Global Phosphoinositide 3-Kinase Inhibitor Players, Product Type & Application
4.5 Global Phosphoinositide 3-Kinase Inhibitor Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Phosphoinositide 3-Kinase Inhibitor Market CR5 and HHI
4.6.3 2024 Phosphoinositide 3-Kinase Inhibitor Tier 1, Tier 2, and Tier 3
5 Phosphoinositide 3-Kinase Inhibitor Market Size by Type
5.1 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2020-2031)
5.3 Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Type (2020-2031)
6 Phosphoinositide 3-Kinase Inhibitor Market Size by Application
6.1 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2020-2031)
6.3 Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Gilead Sciences Inc.
7.1.1 Gilead Sciences Inc. Comapny Information
7.1.2 Gilead Sciences Inc. Business Overview
7.1.3 Gilead Sciences Inc. Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2020-2025)
7.1.4 Gilead Sciences Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio
7.1.5 Gilead Sciences Inc. Recent Developments
7.2 Secura Bio, Inc.
7.2.1 Secura Bio, Inc. Comapny Information
7.2.2 Secura Bio, Inc. Business Overview
7.2.3 Secura Bio, Inc. Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2020-2025)
7.2.4 Secura Bio, Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio
7.2.5 Secura Bio, Inc. Recent Developments
7.3 TG Therapeutics Inc.
7.3.1 TG Therapeutics Inc. Comapny Information
7.3.2 TG Therapeutics Inc. Business Overview
7.3.3 TG Therapeutics Inc. Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2020-2025)
7.3.4 TG Therapeutics Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio
7.3.5 TG Therapeutics Inc. Recent Developments
7.4 Bayer AG
7.4.1 Bayer AG Comapny Information
7.4.2 Bayer AG Business Overview
7.4.3 Bayer AG Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2020-2025)
7.4.4 Bayer AG Phosphoinositide 3-Kinase Inhibitor Product Portfolio
7.4.5 Bayer AG Recent Developments
7.5 Novartis AG
7.5.1 Novartis AG Comapny Information
7.5.2 Novartis AG Business Overview
7.5.3 Novartis AG Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2020-2025)
7.5.4 Novartis AG Phosphoinositide 3-Kinase Inhibitor Product Portfolio
7.5.5 Novartis AG Recent Developments
8 North America
8.1 North America Phosphoinositide 3-Kinase Inhibitor Revenue (2020-2031)
8.2 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2020-2031)
8.2.1 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2020-2025)
8.2.2 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2026-2031)
8.3 North America Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2020-2031)
8.4 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2020-2031)
8.4.1 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2020-2025)
8.4.2 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2026-2031)
8.5 North America Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2020-2031)
8.6 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Country
8.6.1 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2020-2025)
8.6.3 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Phosphoinositide 3-Kinase Inhibitor Revenue (2020-2031)
9.2 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2020-2031)
9.2.1 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2020-2025)
9.2.2 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2026-2031)
9.3 Europe Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2020-2031)
9.4 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2020-2031)
9.4.1 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2020-2025)
9.4.2 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2026-2031)
9.5 Europe Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2020-2031)
9.6 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Country
9.6.1 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2020-2025)
9.6.3 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
9.6.9 Nordic Countries
10 China
10.1 China Phosphoinositide 3-Kinase Inhibitor Revenue (2020-2031)
10.2 China Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2020-2031)
10.2.1 China Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2020-2025)
10.2.2 China Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2026-2031)
10.3 China Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2020-2031)
10.4 China Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2020-2031)
10.4.1 China Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2020-2025)
10.4.2 China Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2026-2031)
10.5 China Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Phosphoinositide 3-Kinase Inhibitor Revenue (2020-2031)
11.2 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2020-2031)
11.2.1 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2020-2025)
11.2.2 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2026-2031)
11.3 Asia Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2020-2031)
11.4 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2020-2031)
11.4.1 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2020-2025)
11.4.2 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2026-2031)
11.5 Asia Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2020-2031)
11.6 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Country
11.6.1 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2020-2025)
11.6.3 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue (2020-2031)
12.2 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2020-2031)
12.2.1 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2020-2025)
12.2.2 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2026-2031)
12.3 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2020-2031)
12.4 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2020-2031)
12.4.1 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2020-2025)
12.4.2 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2026-2031)
12.5 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2020-2031)
12.6 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Country
12.6.1 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2020-2025)
12.6.3 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.